Loading stock data…
ACADIA Pharmaceuticals Inc. (ACAD)
$25.32+1.60 (+6.75%)
Pre-Market$25.56+0.24 (+0.95%)· Last close Jun 26
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ACADIA Pharmaceuticals Inc. in the Healthcare sector is trading at $25.32 with a market capitalization of $3.7B. Wall Street consensus targets $32.00 (20 analysts), implying a +26.4% move over the next 12 months. The stock is currently 11% below its 52-week high of $28.35, remaining 9.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +26.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $268.06M↓ | $283.99M↑ | $278.63M↑ | $264.57M↑ | $244.32M |
| Gross Profit | $243.27M↓ | $257.76M↑ | $256.99M↑ | $243.83M↑ | $223.93M |
| Operating Income | -$4.62M↓ | $17.39M↓ | $35.76M↑ | $32.37M↑ | $19.29M |
| Net Income | $3.64M↓ | $273.57M↑ | $71.78M↑ | $26.67M↑ | $18.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agon...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.67B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
9.70
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
30.10%
Volume
Today's trading volume
7.37M
Recent News
The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout
Acadia stock popped Friday after European regulators unexpectedly said they would recommend approval of the Rett syndrome drug, Daybu.
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and
Sector Update: Healthcare Stocks Gain Friday Afternoon
Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 2.3% and the S
Why Acadia Pharmaceuticals Stock Is Soaring Today
An approval of one of its drugs for a major market is now looking likely.
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe
The European Commission will review the recommendation and is expected to issue a final decision in the coming months.